Mr Mark Kotter is a clinician scientist at the University of Cambridge. His research focusses on stem cells, cellular reprogramming and regenerative medicine. A technology developed by his group merging stem cell with synthetic biology has opened up novel opportunities for highly efficient and consistent production of cells for research, drug development and cell therapy.                  

 

He is the founder of two start-ups based on this technology.  As  a neurosurgeon, Mark specialises in spinal cord injury patients and seeks to develop novel regenerative medicine approaches. 

 

Supported by his Clinician Scientist Award from the National Institute for Health Research (NIHR) and in collaboration with Myelopathy.org and MediciNova, one of these approaches is currently tested in RECEDE Myelopathy, the first regenerative medicine trial for degenerative cervical myelopathy, a common and disabling disease affecting the spinal cord.